NovoCure (NASDAQ:NVCR) Price Target Raised to $52.00

NovoCure (NASDAQ:NVCR) had its target price lifted by HC Wainwright from $46.00 to $52.00 in a research note issued to investors on Thursday morning, Marketbeat reports. The firm currently has a buy rating on the medical equipment provider’s stock. HC Wainwright also issued estimates for NovoCure’s FY2029 earnings at $1.90 EPS.

NVCR has been the topic of several other research reports. Wells Fargo & Company boosted their target price on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, May 4th. Wedbush restated a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a research report on Thursday, April 16th. JPMorgan Chase & Co. initiated coverage on shares of NovoCure in a research note on Monday, July 13th. They set a “neutral” rating and a $17.00 price objective for the company. Zacks Research cut shares of NovoCure from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings raised shares of NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $21.20.

NovoCure Trading Down 11.7%

NVCR opened at $17.65 on Thursday. The firm has a market cap of $2.04 billion, a P/E ratio of -13.58 and a beta of 0.94. NovoCure has a 12 month low of $9.82 and a 12 month high of $21.45. The company has a current ratio of 2.90, a quick ratio of 2.70 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average of $16.64 and a 200 day moving average of $14.14.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.20. The business had revenue of $183.58 million for the quarter, compared to the consensus estimate of $172.44 million. NovoCure had a negative return on equity of 44.02% and a negative net margin of 21.25%.The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.36) earnings per share. As a group, research analysts forecast that NovoCure will post -1.41 EPS for the current year.

Insider Transactions at NovoCure

In related news, Director W Anthony Vernon sold 2,945 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the sale, the director directly owned 197,657 shares of the company’s stock, valued at approximately $3,117,050.89. This trade represents a 1.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director owned 13,861 shares of the company’s stock, valued at approximately $218,587.97. The trade was a 17.52% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 51,943 shares of company stock valued at $893,171. Company insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new position in NovoCure in the 4th quarter worth about $33,000. Kestra Advisory Services LLC purchased a new stake in NovoCure in the 4th quarter valued at about $49,000. Larson Financial Group LLC grew its stake in NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 3,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after acquiring an additional 1,120 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in NovoCure in the 1st quarter worth about $87,000. 84.61% of the stock is currently owned by institutional investors.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.